



SBI Biotech Co., Ltd.  
Changchun Huapu Biotechnology Co., Ltd.

SBI BIOTECH HAS ENTERED INTO A LICENSE AGREEMENT WITH  
CHANGCHUN HUAPU BIOTECHNOLOGY TO EXPAND NOVEL NUCLEOTIDE  
DRUG PIPELINE

TOKYO, JAPAN and CHANGCHUN, JILIN, People's Republic of China, October 6, 2008 - SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., and Changchun Huapu Biotechnology Co., Ltd. announced today that they entered into a license agreement to develop future novel class of nucleotide drugs.

The three licensed compounds, which SBI Biotech acquired from Changchun Huapu, are potential new class of nucleotide drugs, targeting to dendritic cells and B cells, then induce apoptosis of B cell neoplasms and modulate immune responses. Both companies plan to collaboratively develop these compounds in USA, China and/or Japan depending upon indications. Simultaneous multi-national clinical developments will be considered as an option of such collaboration.

“It’s an honor to work with Ken-ichi Arai, founder of SBI Biotech and one of Japan’s leading scientists. We look forward to collaborating with SBI Biotech to develop the novel class of drugs for the treatment of cancers, infections and autoimmune diseases,” said Mr. Weimin Xu, Chairman of Chungchun Huapu.

“We are pleased to collaborate with Changchun Huapu, a company with strong immunological research capabilities and drug discovery programs in Changchun, We intend to create novel treatments in the field of oncology and immunology by combination of nucleotide drugs with therapeutic antibody and dendritic cell immunotherapy,” said Ken-ichi Arai, M.D. and Ph.D., president & CEO, SBI Biotech.

We are working with world top researchers and forming alliance with leading institutions, bioventures and pharmaceutical companies in the world. Our goal is significant expansions as a global drug discovery company by networking in Japan, United States, China and Korea in the fields of drug discovery research and

development.

### **About Nucleotide Drugs**

Nucleotide drugs are currently at drug discovery or development stage as molecular target medicines owing to their specific molecular and biological functions. For example, anti-sense DNAs and siRNAs which regulate gene expression of target molecules, aptamers and CpG oligodeoxynucleotide which specifically bind to target proteins. They are generically referred to as nucleotide drugs.

### **Profile of Changchun Huapu Biotechnology Co., Ltd.**

Changchun Huapu Biotechnology Co., Ltd. is a biotech company, specialized in the development of nucleotide based therapeutics and vaccine for the treatment and prevention of human cancer and infectious diseases. The company was established in 2002 in Changchun, People's Republic of China, and has developed a strong portfolio of IPs and drug pipelines.

Changchun Huapu Biotechnology Co., Ltd

Media: Yan Shao

Phone number: +86-10-58836808

### **Profile of SBI Biotech Co., Ltd.**

SBI Biotech Co., Ltd, the drug subsidiary company of SBI Holdings, Inc. is conducting its business as the global bioventure company by assembling discovery pipelines from Japan, United States, China and Korea. SBI Biotech advances drug discovery and new therapy by utilizing the global network of SBI researchers, receiving investments from venture capital and by collaborating with pharmaceutical companies and university hospitals. For more information on SBI Biotech, please refer to the company's website at [www.sbibiotech.jp](http://www.sbibiotech.jp).

SBI Biotech Co. Ltd.

Media: Atsuko Toda

Phone number: +81-3-5789-3200